Exploring the prognostic value of resting state brain activity in Disorders of Consciousness: A coordinate-based meta-analysis.

Neurosci Biobehav RevJun 26, 2026 (epub)
Clinical ResearchNeurologyPsychiatry

F G Magnani, M Cacciatore, L Clementi et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined the prognostic value of resting state brain activity in 332 patients with Disorders of Consciousness (DoC). It found that patients with good outcomes exhibited increased spontaneous activity in sensory and associative brain areas compared to those with bad outcomes. The study highlights the importance of posterior brain area preservation for prognosis.

Key findings

  • Good Outcome patients showed increased spontaneous activity in sensory and associative areas compared to Bad Outcome patients.
  • The analysis included data from 332 DoC patients, with 192 classified as Bad Outcome.
  • Preservation of posterior brain areas is crucial for prognosis in DoC patients.

Why it matters

Understanding the prognostic indicators in Disorders of Consciousness can guide clinical decision-making and improve patient management strategies. Identifying brain activity patterns associated with recovery may enhance prognostic accuracy.

Source

PubMed · PMID 42361934

Published in Neurosci Biobehav Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.